Quick Facts
  • Primary Location:
    New York-Presbyterian Hospital/Columbia University Medical Center
  • Expertise:
    Thoracic Cancer
    Immunotherapy
  • Speciality:
    Hematology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    Rutgers New Jersey Medical School

Get to Know Dr. Brian Henick

Medical oncologist Dr. Brian Henick specializes in thoracic malignancies, including lung cancer and mesothelioma, and in personalizing patient care through novel therapeutics.

Henick believes in a multidisciplinary approach to treatment that includes the computational study of cancer immunobiology, the latest advancement in cancer care.

With every patient he serves, his goal is improving the current treatment strategy by maximizing the vast resources of one of the country’s leading cancer centers and its mesothelioma doctors.

The National Cancer Institute has recognized the Columbia University Herbert Irving Comprehensive Cancer Center as an elite Comprehensive Cancer Center for more than 30 years.

Henick takes pride in staying attuned to the values and needs of each individual. His areas of treatment expertise include esophageal cancer and thymoma through the field of hematology.

He also serves as an associate professor of medicine at the Columbia University Irving Medical Center.

Contact Brian Henick

Specialties of Dr. Brian Henick

  • Immunotherapy
  • Lung cancer
  • Pleural mesothelioma
  • Esophageal cancer
  • Hematology
  • Oncology
  • Thoracic cancers

Dr. Brian Henick’s Experience and Medical Education

  • Columbia University Herbert Irving Comprehensive Cancer Center
  • Rutgers New Jersey Medical School (M.D.)
  • Yale New Haven Hospital (Fellowship, residency, internship)

Awards and Other Recognitions

  • ASCO Journals Editorial Fellowship
  • Conquer Cancer/ASCO Foundation Merit Award
  • Conquer Cancer/ASCO Young Investigator Award
  • Society for Immunotherapy of Cancer Sparkathon
  • Gold Humanism Honor Society

Publications of Dr. Brian Henick

  • Henick, B. (2020, February 11). Elite Intratumoral T-cell Clonotypes (The 1%) Effect “Trickle-Down Cytotoxicity.” Clinical Cancer Research.
  • Zugazagoitia, J. et al. (2019, October 9). Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology.
  • Henick, B. et al. (2014, December 18). The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Thoracic Targets.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?